Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks
Abstract The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids…
cannabidiol pharmacokinetics
Results of an Exploratory Crossover Pharmacokinetic Study Evaluating a Natural Hemp Extract-Based Cosmetic Product: Comparison of Topical and Oral Routes of Administration †
Abstract Background: Hemp extracts are used topically as cosmetic products and may be ingested as dietary supplements. Some users report…
Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial
Abstract Background: Cannabidiol (CBD) has anti-nociceptive and anti-inflammatory characteristics, and was reported to provide analgesia in dogs with osteoarthritis. However,…
Cannabidiol lymphatic transport after oral administration assessed using a novel thoracic lymph duct cannulated conscious pig model
Abstract Lymphatic transport of drugs after oral administration is an important physiological process in highly lipophilic compounds, such as cannabidiol…
A Randomized, Single-Dose, Single-Sequence, Two-Arm (Fasting and Fed), Open-Label Study on the Oral Pharmacokinetics of a Nanodispersible Cannabidiol Solution (150 mg/mL)
Abstract Introduction: Cannabidiol (CBD), a non-psychoactive phytocannabinoid, attributed to its therapeutic benefits and positive safety profile is being studied for…
Pharmacokinetics and pharmacodynamics of cannabigerol (CBG) in the C57BL/6Crl mouse
Abstract Introduction: Cannabis holds therapeutic potential; however, activation of the type 1 cannabinoid receptor (CB1R) via Δ9-tetrahydrocannabinol (THC) is also…
Pharmacological and Pharmacokinetic Profile of Cannabidiol in Human Epilepsy: A Review of Metabolism, Therapeutic Drug Monitoring, and Interactions with Antiseizure Medications
Abstract Cannabidiol (CBD) has transitioned from anecdotal use to an evidence-based adjunctive therapy for Lennox–Gastaut syndrome, Dravet syndrome, and tuberous…
A Phase 1B Trial of Cannabidiol for Symptom Management in Kidney Failure
Keywords: cannabidiol, chronic kidney failure, clinical trial, pharmacokinetics, sleep, symptom burden Authors: Brendan Smyth, Taewon Yi, Kristy P. Robledo, Rebecca…
Using a PBPK Model Incorporating Lymphatic Absorption to Predict Food Effect, Multiple Dosing, and Hepatic Impairment of Cannabidiol
Abstract Cannabidiol (CBD) is one of the most extensively studied cannabinoids and is used for myriad conditions. Its oral pharmacokinetics…
Liposomal-synthetic-cannabidiol: preliminary translational evidence of efficacy, tolerability and pharmacokinetics following repeated subcutaneous injections in two goats
Abstract Cannabidiol (CBD), the primary non-psychoactive component of Cannabis sativa, has been gaining popularity as an analgesic in treatment of…